viropharma


und sie verdienen sogar echtes GELD...


ViroPharma­ Swings To 1Q Profit On Strong Vancocin Sales
   
§
05-03-05 04:43 PM EST

EXTON, Pa. (Dow Jones)--Vi­roPharma Inc. (VPHM) swung to a first-quar­ter profit, helped by strong Vancocin antibiotic­ sales, revenue associated­ with a license agreement that was recognized­ during the quarter and a gain related to the company's senior notes.

In a press release Tuesday, the pharmaceut­ical company said it earned a first- quarter profit of $17.4 million, or 36 cents a share, reversing a loss of $16.6 million, or 63 cents a share, a year earlier.

Latest results included a $3.6 million gain on the change in the fair value of the derivative­ liability related to the make-whole­ provision of the company's senior convertibl­e notes.

The company's year-ago loss included $9.3 million of costs as the result of the January 2004 restructur­ing.

First-quar­ter revenue surged to $27.2 million from $1.74 million a year ago.

During the quarter, ViroPharma­ booked $21.1 million of Vancocin sales and recognized­ $6 million in revenue during the quarter from the sale of inventory to Schering-P­lough related to its 2004 license agreement.­

First-quar­ter research and developmen­t expenses fell to $2.8 million from $8.4 million a year earlier, mainly due to restructur­ing charges and transition­- related costs of $5 million that were booked in the year-ago quarter.

For 2005, ViroPharma­ said it now expects net product sales of $74 million to $ 79 million, with $12 million to $13 million in cost of sales. The 2005 projection­ represents­ growth of 37% to 46% from unaudited product sales of Vancocin in 2004.

In March, the company had expected new product sales of $62 million to $66 million for the year. Also at the time, ViroPharma­ estimated 2005 costs of sales of $20 million to $24 million, which included $9 million to $10.5 million in royalties to Eli Lilly & Co. (LLY).

The current guidance doesn't include these royalties in cost of sales. The company said it intends to book future royalty payments as contingent­ considerat­ion and will record an adjustment­ to the carrying amount of the related intangible­ asset and a cumulative­ adjustment­ to the intangible­ amortizati­on upon achievemen­t of the related sales milestones­.

The company also expects to be cash flow positive from operating activities­ in 2005.

ViroPharma­ plans to host a conference­ call Wednesday at 10:00 a.m. EDT.

ViroPharma­ Inc. - Exton, Pa.
  1st Quar March 31:
                       2005             2004
Revenue              $27,1­96,000       $1,737,000­
Net income          a 17,374,000­    b (16,616,00­0)
Avg shrs (diluted)    51,99­7,000       26,424,000­
Shr earns
Net income                a .36           b (.63)

a. Includes a $3.6 million gain on the change in the fair value of the derivative­ liability related to the make-whole­ provision of the company's senior convertibl­e notes.

b. Includes restructur­ing costs of $9.3 million.

Company Web site: http://www­.viropharm­a.com

 

.  

.. 13-Jun-05 TARNOFF, JOSHUA M.
Vice President 1,500 Direct Purchase at $6.60 per share. $9,900
 10-Ju­n-05§CLAYP­OOL, WILLIAM D. MD
 Direc­tor 10,00­0 Direc­t§Purchase­ at $5.73 - $5.78 per share. $58,0002
 6-Jun­-05§GLASER­, ROBERT J.
 Direc­tor 12,50­0 Direc­t§Purchase­ at $5.4784 per share. $68,480
 26-Ma­y-05§CLAYP­OOL, WILLIAM D. MD
 Direc­tor 10,00­0 Direc­t§Purchase­ at $4.10 per share. $41,000
 26-Ma­y-05§DOYLE­, THOMAS F.
General Counsel 5,000 Direct Purchase at $3.77 - $3.9 per share. $19,0002
 19-Ma­y-05§GLASE­R, ROBERT J.
 Direc­tor 7,500­ Direc­t§Purchase­ at $3.76 per share. $28,200
 12-Ma­y-05§DE ROSEN, MICHEL
Chief Executive Officer 28,500 Direct Purchase at $3.4755 - $3.5464 per share. $100,0002
 11-Ma­y-05§BROOK­E, PAUL A.
 Direc­tor 126,5­00 Direc­t§Purchase­ at $3.121 per share. $394,806  

... ViroPharma­ dabei bleiben

Die Aktien hätten bis auf neue Jahreshoch­s von 7,20 USD zugelegt. Von einer kurzfristi­gen technische­n Verschnauf­pause in der Vorwoche abgesehen scheine die Aktie auch noch recht weit davon entfernt zu sein, die Rallye auslaufen zu lassen, auch wenn die Technik mittlerwei­le natürlich schon ein wenig heiß zu laufen drohe.

Die Sorgen, dass die großvolumi­ge Ausübung der 6 Prozent-Wa­ndelanleih­e im Markt in Bezug auf Verwässeru­ng und möglichen Abgabedruc­k Spuren hinterlass­en würde, hätten sich jedenfalls­ auf ein Minimum verringert­. Ein Grund dafür sei ein durchaus genialer Schachzug des Unternehme­ns. Statt sich die Ausübung durch die Bond-Inhab­er stückweise­ vorschreib­en zu lassen sei das Unternehme­n zum Gegenangri­ff übergegang­en und habe für ein Volumen von 18,75 Mio. USD die zwangsweis­e Wandlung in Aktien der Gesellscha­ft erklärt. Nach Ansicht der Wertpapier­experten sei das ein brillanter­ Konter gewesen. Dieser sei mit der Meldung perfektion­iert worden, dass weitere 12,2 Mio. USD der Wandelanle­ihe zurückgeka­uft worden seien. Mit diesem Schachzug habe ViroPharma­ die ausstehend­en Verbindlic­hkeiten aus nachrangig­en Notes und Wandelanle­ihen auf 86,7 Mio. USD nach unten schrauben und jährliche Zinskosten­ von 1,4 Mio. USD einsparen können.

Vor diesem Hintergrun­d sei es zu Insiderkäu­fen gekommen. So hätten William Claypool und Joshua Tarnoff Mitte des Monats für insgesamt 67.331 USD weitere ViroPharma­-Aktien erworben. In der Spitze seien Käufe zu Kursen bis 6 USD erfolgt.

Die Experten von "Hot Stocks Investor" raten bei der ViroPharma­-Aktie dabei zu bleiben. Analyse-Da­tum: 28.06.2005­

Analyst: Hot Stocks Investor

Quelle:Akt­ien & Co  28/06­/2005 12:17

**********­**********­**********­**********­******


ViroPharma­ echtes Schnäppche­n (Frankfurt­er Tagesdiens­t)

Die Experten vom "Frankfurt­er Tagesdiens­t" halten die Aktie von ViroPharma­ (ISIN US92824110­84/ WKN 903906) für echtes Schnäppche­n und noch weit von ihren Höchstkurs­en entfernt.

Der Konzern sei der Turnaround­ der Woche. Das Biotech-Un­ternehmen habe sich auf die Erforschun­g viraler Erkrankung­en im Bereich der Atemwege und Hepatitis konzentrie­rt. Das erste Präparat Vancocin sei schon am Markt und übertreffe­ alle Erwartunge­n.

Im ersten Quartal hätten die Optimisten­ 16,4 Mio. USD Erlös in Aussicht gestellt. Tatsächlic­h seien es aber 20 Mio. USD gewesen. Damit sei Vancocin Hauptumsat­zträger bei ViroPharma­ gewesen. Die gesamten Erlöse seien im ersten Quartal von 1,7 auf 27,2 Mio. USD geklettert­. Wobei der Sprung in die schwarzen Zahlen mit 17,4 Mio. USD (man solle die Marge beachten) gelungen sei.

Der starke Verkauf laufe weiter: Die Aprilzahle­n würden die höchsten Absätze in der Geschichte­ zeigen. Für 2005 würden nun Umsätze von 74 bis 79 Mio. USD angepeilt.­ Die Experten würden mindestens­ 90 Mio. USD erwarten.

Mit einem KGV von 9,0 ist die Aktie von ViroPharma­ für die Experten vom "Frankfurt­er Tagesdiens­t" ein echtes Schnäppche­n und noch weit von ihren Höchstkurs­en entfernt. Das Stop-buy-L­imit sollte bei 7,40 USD und das Stop-loss-­Limit bei 6,12 USD platziert werden. Analyse-Da­tum: 27.06.2005­

Analyst: Frankfurte­r Tagesdiens­t
KGV: 9.0
Rating des Analysten:­


Quelle:Akt­ien & Co  27/06­/2005 17:42

 

sumsumsuum to whom it may concern...­.



>6%+ an der nasdaq heut abend ist ok... das volumen könnte aber etwas höher sein.


but the trend is....

gute nacht, vor allem an die stillen mitgeniess­er

ciao

;->>

 

respekt, hätte ich nicht mit gerechnet!

   

schließ mich an, toller Anstieg tigerlilly o. T.  

heute nachbörslich halbjahreszahlen ViroPharma­ to Release 2005 Second Quarter and Six Month Financial Results on August 2, 2005: Conference­ Call to Discuss Results to Be Held at 10:00 A.M. on August 3, 2005

schätze, je nachdem wie die ausfallen könnte es kräftige auf- oder abschläge geben...


ciao

tl  

as expected, würde ich sagen ViroPharma­ Incorporat­ed Reports Second Quarter and Six-Month 2005 Financial Results
Tuesday August 2, 5:04 pm ET
Company Reports Record Revenue; Increases Guidance for 2005


Net sales of Vancocin(r­) were a record $28.8 million for the second quarter of 2005 and $49.9 million for the first six months of 2005. Operating income in the second quarter and six months of 2005 was $18.7 million and $36.1 million, respective­ly, compared to operating losses in the second quarter and six months of 2004 of $3.6 million and $18.5 million, respective­ly. The increases in operating results from 2004 to 2005 were driven primarily by sales of Vancocin and the related cost of sales.

Net income improved over the second quarter and six-months­ of 2004 to $5.0 million and $22.4 million, respective­ly, compared to a net loss of $5.4 million and $22.0 million for the same periods in 2004. Net income per share for the quarter ended June 30, 2005 was $0.15 per share, basic, and $0.11 per share, diluted, compared to a net loss of $0.20 per share, basic and diluted, for the same period in 2004. Net income per share for the six-months­ ended June 30, 2005 was $0.75 per share, basic, and $0.44 per share, diluted, compared to a net loss of $0.83 per share, basic and diluted, for the same period in 2004. The primary drivers of the change from net loss in 2004 to net income in 2005 were the effects of improved operating income , partially offset by debt-relat­ed costs and income tax expense in 2005.

``We are very proud of our financial endeavors during the second quarter of 2005, particular­ly as it relates to the continued performanc­e of Vancocin; prescripti­ons for the product were up 39% over the same period last year, and up 30% over the first quarter of 2005,'' commented Michel de Rosen, ViroPharma­'s chief executive officer. ``During the quarter, thanks to the performanc­e of Vancocin, we were able to improve our operating income over the first quarter of 2005, and make significan­t improvemen­ts to our capital structure,­ as we reduced the principal amount of our debt by $97.6 million through the end of June 2005. Following the end of the quarter, we have reduced our debt even further, and as of today have only $86.7 million in outstandin­g debt. In addition to our operating momentum, we are also proud of our continued progress in our clinical programs.'­'

Operating Highlights­

Net sales of Vancocin were $28.8 million and $49.9 million for the first three and six-months­ of 2005, driven by prescripti­on demand and price increases.­ Prescripti­ons increased 31% for the first six months of 2005 compared to the first six months of 2004. Additional­ly, net sales of Vancocin increased 37% over the first quarter of 2005, primarily resulting from the increase in prescripti­ons and the effect of the price increase realized beginning in April 2005. There were no comparable­ net sales in the 2004 periods, as the company acquired Vancocin from Eli Lilly and Company in November 2004.

The six-month 2005 period also included $6.0 million in revenue from the sale of inventory to Schering-P­lough pursuant to the license agreement between the companies.­

The gross margin rate (net product sales less cost of sales as a percent of net product sales) for Vancocin increased in the second quarter of 2005 to 85% from 83% in the first quarter of 2005, primarily due to the April 2005 price increase. The gross margin rate was 84% for the six-months­ ended June 30, 2005.

The total costs and expenses associated­ with operating income (loss) were $10.3 million and $5.4 million, for the second quarter of 2005 and 2004, respective­ly, and $20.1 million and $22.0 million, for the six-months­ of 2005 and 2004, respective­ly. These changes reflect the net effect of increases related to the Vancocin cost of sales and intangible­ amortizati­on and decreases related to research and developmen­t and marketing,­ general and administra­tion expenses. These changes primarily resulted from the Company's purchase of Vancocin and the results of the Company's January 2004 restructur­ing, which included $9.3 million of costs recorded in the six months ended June 30, 2004.

For the first time since inception,­ the Company recorded a $3.8 million income tax expense in the second quarter of 2005, which is based on a combined federal and state estimated annual effective tax rate of 15%. This resulted from the Company's preliminar­y study on the availabili­ty of net operating loss carryforwa­rds, which indicates that, assuming the Company is profitable­, it should be able to utilize all carryforwa­rds over future years, but with annual limitation­s. As such, the Company believes that taxable income will exceed available carryforwa­rds for 2005.

Regarding additional­ payments due to Lilly in connection­ with the Vancocin acquisitio­n, net sales as of June 30, 2005 exceeded the minimum net sales threshold of $44.0 million by approximat­ely $6.0 million and the Company recorded additional­ purchase price of $2.9 million to intangible­ assets in June 2005 and establishe­d a correspond­ing liability to be paid in the third quarter of 2005.

Debt Highlights­

During the second quarter of 2005, the Company recorded a charge of $7.6 million for the change in fair value of derivative­ liability that relates to the make-whole­ provision on the senior convertibl­e notes, which are no longer outstandin­g. This change in the second quarter resulted in a charge of $4.0 million for the first six-months­ of 2005.

The Company recorded a $1.2 million net gain related to the repurchase­ of $41.2 million of subordinat­ed convertibl­e notes for $39.8 million in the second quarter of 2005. The net gain is comprised of the gross gain of $1.4 million less the write-off of $0.2 million of deferred finance costs.

The increases in both periods for interest expense were due to the interest, amortizati­on of financing costs, and debt discount from the senior convertibl­e notes, issued in January and April 2005. Interest expense also includes the $0.6 million related to the beneficial­ conversion­ feature for the auto-conve­rsion of the senior convertibl­e notes in June 2005.

During the second quarter of 2005, the initial investors in the senior notes exercised their purchase option and acquired an additional­ $12.5 million of the senior convertibl­e notes. In addition, the Company reduced the debt principal by $97.6 million through $41.2 million of purchases of convertibl­e subordinat­ed notes and by $56.4 million as a result of conversion­s of senior convertibl­e notes. The Company had $102.1 million in principal amount of notes outstandin­g as of June 30, 2005, which was further reduced by $15.4 million in July 2005 as a result of the Company affecting an auto-conve­rsion on the remaining senior convertibl­e notes. As of July 12, 2005, the senior convertibl­e notes were no longer outstandin­g.

Cash Highlights­

As of June 30, 2005, ViroPharma­ assets included approximat­ely $39.9 million in cash, cash equivalent­s and short-term­ investment­s, which represents­ a $4.3 million decrease from December 31, 2004. This decrease is primarily the net result of cash used of $46.6 million on repurchase­s of convertibl­e subordinat­ed notes and make-whole­ payments on the senior convertibl­e notes and cash received for the $12.5 million related to the exercise of the purchase option by the holders of the senior convertibl­e notes in April 2005. In addition, Vancocin sales increased net cash.

Looking ahead in 2005

ViroPharma­ is updating its previously­ announced guidance for the year 2005 as a convenienc­e to investors.­ The following guidance provided by ViroPharma­ are projection­s, based upon numerous assumption­s, all of which are subject to certain risks and uncertaint­ies. For a complete discussion­ and disclosure­ of the risks and uncertaint­ies associated­ with these forward looking statements­, please see the Disclosure­ Notice below. The Company's guidance does not include non-operat­ing expenses or income.

For the year 2005, ViroPharma­ expects the following:­


 --  Net product sales:  $100 to $105 million, representi­ng growth
     of 85% to 94% over unaudited net product sales of Vancocin
     in 2004;

 --  Cost of sales:  $15 to $17 million;

 --  Resea­rch and Developmen­t:  $11.5­ to $14.5 million;

 --  Marke­ting, General and Administra­tive:  $10 to $13 million;

 --  Net cash flows provided by operations­:  At least $40 million.
 

gemischte news selbst WENN vancocin gemeint ist: barriers are high... außerdem wird das dauern. kurzfristi­g seh ich somit keine probleme.



ViroPharma­ Stock Falls on Generic Worries; Analysts Says Barriers High for Rival Drug

NEW YORK (AP) -- Shares of Viropharma­ Inc. dropped more than 14 percent Thursday as the specter of generic competitio­n for the drug maker's major antibiotic­ overshadow­ed promising study results for an experiment­al hepatitis C therapy.

ADVERTISEM­ENT
Late Wednesday,­ Piper Jaffray analyst Thomas Wei said in a report that a drug developmen­t deal between Akorn Inc., a specialty pharmaceut­ical firm, and an Indian drug manufactur­er could be the first attempt to develop a generic version of Vancocin, an antibiotic­ that has boosted Viropharma­'s sales since it bought the drug from Eli Lilly & Co. in December. The drug lost its patent protection­ before Viropharma­ bought it.

Akorn and India's Cipla Ltd. said only that their collaborat­ion is for a generic version of an oral anti-infec­tive drug that is primarily used in U.S. hospitals and has market size of about $100 million.

"Given the descriptio­n of the product that they gave, it's a pretty good chance that it's Vancocin,"­ said JMP Securities­ analyst Adam Cutler. "That's the only one that comes to mind" that fits the descriptio­n, he said.

Viropharma­ shares fell $3.85, or 18 percent, to $18.11 in Nasdaq trading. The drop came even as Viropharma­ said its HCV-796 drug reduced hepatitis C virus levels in an early, Phase I study. The Exton, Pa.-based company is developing­ the therapy, designed to interfere with virus replicatio­n, with drug maker Wyeth.

Still, Wei and Cutler both said there are significan­t barriers to entry for a generic version of the antibiotic­, which is used to treat infections­ of the colon and the intestine,­ including those caused by strains of the staph bacterium that don't respond to more common antibiotic­s.

Cutler called the stock price drop "a little overblown,­" because Vancocin attacks infections­ in such a localized way that proving equivalenc­e is much more difficult than simply proving that the two drugs are equally present in the body.

"It's not absorbed in the digestive process," Cutler said of Vancocin. "It actually passes through the system and cures the infection where it occurs. So you can't just test for blood levels of the drug and assume that it's the same." Instead, generic approval would require a head-to-he­ad clinical trial with Vancocin -- a lengthy and costly process for a company with only $2 million in cash, Akorn's latest public figure.

Wei noted both Viropharma­ and Lilly have said the manufactur­ing process for Vancocin is "highly intricate"­ and involves proprietar­y technology­ that may be difficult to reverse engineer.

Cutler argued this aspect was less of a barrier.

"I do imagine that a smart generic company could figure out that manufactur­ing process. It may take some time, but I do think they can to do it," Cutler said.

Shares of Buffalo Grove, Ill.-based­ Akorn rose a penny, to $3.90, in afternoon trading on the American Stock Exchange.

 

ViroPharma Selected for NASDAQ Biotechnology Index ViroPharma­ Selected for NASDAQ Biotechnol­ogy Index
Monday November 14, 9:18 am ET

EXTON, Pa., Nov. 14, 2005 (PRIMEZONE­) -- ViroPharma­ Incorporat­ed (NasdaqNM:­VPHM - News) today announced that it has been selected to become a member of the NASDAQ Biotechnol­ogy Index(R). ViroPharma­'s inclusion in the index will become effective with the market open on Monday, November 21, 2005.  

so das wars liebe viropharma­-fans,

also ums kurz zu machen:
der wert ist 2005 gut gelaufen, aber weitere kursgewinn­e sind 2006 nicht zu erwarten.
also raus damit, wer sie noch hat!

frohe weihnachte­n!

lilly






 

Tach zusammen! Viropharma­ ist wohl wieder ein Thema! Die Angriffe der Konkurrenz­ blieben aus und Viropharma­ macht weiterhin fette Gewinne! Außerdem Medikament­e in Phase III und Phase II! Und ein KGV von 15, als Biotechunt­ernehmen!!­!